Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Thromboembolic events in patients with advanced non-small cell lung cancer receiving palliative chemoimmunotherapy with pembrolizumab.

Tae-Hwan Kim, Cheongin Yang, Yong Won Choi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24068

e24068 Background: Thromboembolic events (TEEs) represent a serious and clinically significant complication in patients (p...

Clinicopathologic features, treatment patterns, and outcomes in young women with metastatic breast cancer: A National Cancer Database analysis.

Cher Ying Foo, Ojasav Sehrawat, Waqar Haque et al. Jun 01, 2026 pp. 1115-1115 10.1200/jco.2026.44.16_suppl.1115

1115 Background: Young women with metastatic breast cancer (MBC) represent a distinct and understudied population and ofte...

“When I’m translating, I’m a daughter as well”: Perspectives of caregivers supporting patients with limited language proficiency.

Rinat Nissim, Paige Chu, Marianna Calamia et al. Jun 01, 2026 pp. 12096-12096 10.1200/jco.2026.44.16_suppl.12096

12096 Background: Family caregivers of people with advanced cancer provide essential support but often experience signific...

Dose-dependent effect of dinutuximab-IR700 photoimmunotherapy on GD2-expressing tumors.

Arjun Pant, Catherine Yip, Bhuvitha Chagantipati et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14556

e14556 Background: Near-infrared photoimmunotherapy (PIT) is a novel, molecularly targeted cancer therapy. It combines tum...

Safety and efficacy of chemotherapy in metastatic colorectal cancer with liver dysfunction due to hepatic metastases: A systematic review.

Adrian Bailey, Robert Hovey, Ru Min et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15620

e15620 Background: Patients with metastatic colorectal cancer (mCRC) and severe hepatic dysfunction from liver metastases...

Enabling hybrid AI–radiologist endpoints in clinical trials imaging workflows.

Bharath Ramakrishna, Dhaval Mayatra, Hardik Joshi et al. Jun 01, 2026 pp. 2019-2019 10.1200/jco.2026.44.16_suppl.2019

2019 Background: Imaging endpoints in oncology clinical trials commonly rely on a 2 + 1 radiologist reading paradigm, in w...

Breast cancer mortality among patients with mental and behavioral disorders in the United States: An age-stratified national analysis (1999–2023).

Unsa Arif, Madho Mal, Pari Kotak et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13091

e13091 Background: Breast cancer is the most commonly diagnosed cancer and a leading cause of cancer-related mortality amo...

Neoadjuvant cadonilimab plus CapeOX in patients with clinical stage III gastric or esophagogastric junction adenocarcinoma (GC/EGJC): A prospective, single-arm phase II study.

Liying Zhao, Yanfeng Hu, Jiang Yu et al. Jun 01, 2026 pp. 4089-4089 10.1200/jco.2026.44.16_suppl.4089

4089 Background: Perioperative PD-L1 inhibitor plus chemotherapy has shown survival benefit in PD-L1-positive patients wit...

Thalamic neuroepithelial cysts: Endoscopic management strategies and clinical outcomes.

Sami Almasri, Katherine L. Wei, Om H. Gandhi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14046

e14046 Background: Thalamic neuroepithelial cysts are rare congenital lesions that can cause significant neurological morb...

Outcomes of neoadjuvant checkpoint inhibitor therapy followed by definitive chemoradiation in locally advanced head and neck squamous cell carcinoma (HNSCC).

James Cevallos, Ethan Gomez, Peter Cooke et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18014

e18014 Background: Approximately 70,000 Americans are diagnosed with HNSCC annually. While the KEYNOTE-689 trial establish...

Molecular biomarker testing to predict outcomes in gliomas: A SEER registry study in Kentucky.

John L. Villano, Feitong Lei, Julia Magsam et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14095

e14095 Background: Molecular testing has been required since 2021 for the diagnosis of many primary CNS tumors, and in 201...

Transcriptomic signature of temozolomide treatment-effect heterogeneity in IDH-wildtype glioblastoma.

Amirhossein Zare, Seyed Reza Salarikia, Amirhesam Zare et al. Jun 01, 2026 pp. 2084-2084 10.1200/jco.2026.44.16_suppl.2084

2084 Background: Adjuvant temozolomide (TMZ) is standard of care for IDH-wildtype glioblastoma (GBM), yet clinical benefit...

The PROFOUND study: A large-scale prospective multicenter case-control trial of a multi-cancer early detection (MCED) test in China.

Kezhong Chen, Xiang-Yu Zhao, Guo-Yue Lv et al. Jun 01, 2026 pp. 10541-10541 10.1200/jco.2026.44.16_suppl.10541

10541 Background: Early cancer detection reduces morbidity and mortality, but current recommended screening in China misse...

Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and liver metastasis: Subgroup analysis of the phase 3 CheckMate-9ER trial.

Amishi Yogesh Shah, Bernard Escudier, Thomas Powles et al. Jun 01, 2026 pp. 4530-4530 10.1200/jco.2026.44.16_suppl.4530

4530 Background: In the phase 3 CheckMate 9ER trial (NCT03141177), C+N treatment significantly improved progression-free s...

From local pixels to global patterns: Vision transformer–based modeling for lung cancer classification on computed tomography.

Sarveswar Chinnaswamy Dhandapani, Tanzeela Mariam Shuja, Elangovan Krishnan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20014

e20014 Background: Lung cancer remains the leading cause of cancer-related mortality worldwide, driven largely by delayed...

A prospective, single-arm, phase II exploratory clinical study on the efficacy and safety of neoadjuvant adebrelimab combined with cisplatin and docetaxel in patients with clinical stage IVB oral squamous cell carcinoma.

Zi-Li Yu, Nian-Nian Zhong, Gaili Chen et al. Jun 01, 2026 pp. 6048-6048 10.1200/jco.2026.44.16_suppl.6048

6048 Background: Oral squamous cell carcinoma (OSCC) is one of the most common malignant tumors of the head and neck. Stag...

ctDNA clearance durability and progression-free survival in unresectable or metastatic cutaneous malignancies.

Joshua Espinola, Hongkun Wang, Jafar Al-Mondhiry et al. Jun 01, 2026 pp. 9591-9591 10.1200/jco.2026.44.16_suppl.9591

9591 Background: Circulating tumor DNA (ctDNA) has emerged as a sensitive biomarker for disease monitoring and prognostica...

Predictors of surgery refusal and disease-specific survival outcomes in inflammatory breast cancer: A nationally representative cohort study.

Maria Agustina Callizo Bedoya, Mitchell Allan Taylor, Kate Woods et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12725

e12725 Background: Inflammatory breast cancer (IBC) is a rare but highly aggressive subtype of breast cancer characterized...

Demographic and clinical factors impacting survival in malignant pheochromocytoma: A population-based analysis.

Ahmad Abed, Berkha Rani, Sonia Babu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22605

e22605 Background: Malignant pheochromocytoma is a rare and potentially aggressive neuroendocrine tumor arising from chrom...

Final results of a phase 2 trial of cabozantinib plus nivolumab (CaboNivo) in patients with non–clear cell renal cell carcinoma (nccRCC).

Darren R. Feldman, Martin H. Voss, Marie Carlo et al. Jun 01, 2026 pp. 4521-4521 10.1200/jco.2026.44.16_suppl.4521

4521 Background: CaboNivo improved objective response rate (ORR), progression-free survival (PFS), and overall survival (O...

The CNS exile: An AI-driven audit of active brain metastasis exclusions in modern NSCLC immunotherapy clinical trials.

Andrew Ng, Sudeep Kumar Siddappa Malleshappa Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13746

e13746 Background: Up to 50% of patients with metastatic non-small cell lung cancer (NSCLC) will develop brain metastases...

Age-specific trends in liver cancer mortality in the United States, 1999–2023: A Joinpoint regression analysis.

Julie Ying Zhang, Tuan Vinh, Li Liu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16334

e16334 Background: Liver cancer remains a leading cause of cancer-related mortality in the United States. Although overall...

Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS).

Myong Cheol Lim, Ji Hyun Kim, Boram Park et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5643

TPS5643 Background: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) during interval cytoreductive surger...

Camrelizumab combined with capecitabine as maintenance therapy for metastatic nasopharyngeal carcinoma: A phase II single-arm clinical trial.

Xuecen Wang, Yangchan Li, Yun Huang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18016

e18016 Background: Metastasis is the main cause of death in nasopharyngeal carcinoma (NPC). The current first-line treatme...

Barriers to comprehensive genomic profiling implementation in Japan and perspectives on systemic reform: A longitudinal analysis of nationwide physician surveys (2019–2025).

Ayaka Igarashi, Karin Sakai, Mitsunori Morita Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15083

e15083 Background: Comprehensive Genomic Profiling (CGP) was reimbursed in Japan in 2019. By 2025, physician awareness rea...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page